Head and Neck Cancer Clinical Trials

A listing of Head and Neck Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
A New Membrane Obturator Prothesis Concept for Soft Palate Defects

When soft palate defects lead to palatal insufficiency, the patient's quality of life is affected by difficulties swallowing, hypernasality, and poor intelligibility of speech. If immediate surgical reconstruction is not an option, the patient may benefit from the placement of a rigid obturator prosthesis. Unfortunately, the residual muscle stumps are …

stiff
obturator prosthesis
  • 0 views
  • 16 Sep, 2021
  • 2 locations
Continuous 24h Intravenous Infusion of Mithramycin an Inhibitor of Cancer Stem Cell Signaling in People With Primary Thoracic Malignancies or Carcinomas Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Background Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect. It was discovered that only people with certain genes got this side effect. Researchers want …

mitomycin c
lung carcinoma
calcium
antineoplastic
carcinoma
  • 44 views
  • 21 Sep, 2021
  • 1 location
Carboplatin Nab-Paclitaxel Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

for squamous lung cancer, but experimental for head and neck cancer. Durvalumab is an experimental drug that uses the body's own immune system to fight the cancer. Doctors hope that combining

squamous cell carcinoma of the head and neck
chemotherapy drug
durvalumab
adjuvant therapy
skin cancer
  • 101 views
  • 22 Sep, 2021
  • 2 locations
APG-2449 in Patients With Advanced Solid Tumors

APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It …

solid tumour
cancer
brain metastases
lung carcinoma
cancer of the ovary
  • 10 views
  • 20 Sep, 2021
  • 7 locations
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal cancer, cervical cancer, vaginal cancer, vulvar cancer, penile cancer, Merkel cell carcinoma, Kaposi sarcoma, and

leiomyosarcoma
cancer
edema
doxorubicin
antiretroviral therapy
  • 0 views
  • 22 Sep, 2021
  • 1 location
A Study of Patients Receiving High-Dose Rate Brachytherapy

Background One standard way of giving radiation is to combine external beam treatments with internal brachytherapy treatments, which involve short-range radiation therapy that gives a high dose of radiation directly to a cancer or to the area where cancer cells were removed. Brachytherapy is done by placing hollow implant device(s) …

carcinoma
ebrt
cancer
metastasis
treatment regimen
  • 47 views
  • 20 Sep, 2021
  • 1 location
Safety PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

This is a First-in-Human Phase IA/IB open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

solid tumour
lung carcinoma
breast cancer
pd-l1
carcinoma
  • 2 views
  • 25 Sep, 2021
  • 9 locations
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

cancer
gemcitabine
metastatic pancreatic adenocarcinoma
programmed cell death 1 ligand 1
cdx-301
  • 399 views
  • 17 Sep, 2021
  • 11 locations
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary …

solid tumour
cancer
carcinoma
squamous cell carcinoma
pf-06801591
  • 17 views
  • 23 Sep, 2021
  • 19 locations
A Study of SGN-STNV in Advanced Solid Tumors

This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well …

cancer
erbb2
lung carcinoma
cancer of the ovary
human chorionic gonadotropin
  • 0 views
  • 22 Sep, 2021
  • 6 locations